| Literature DB >> 29020949 |
Oumy Niass1,2, Philippe Saint-Pierre3, Makhtar Niang1, Fode Diop1, Babacar Diouf1, Michel Matar Faye1, Fatoumata Diène Sarr4, Joseph Faye4, Nafissatou Diagne5, Cheikh Sokhna5, Jean-François Trape5, Ronald Perraut1, Adama Tall4, Abdou Kâ Diongue2, Aïssatou Toure Balde6.
Abstract
BACKGROUND: Evaluation of local Plasmodium falciparum malaria transmission has been investigated previously using the reversible catalytic model based on prevalence of antibody responses to single antigen to estimate seroconversion rates. High correlations were observed between seroconversion rates and entomological inoculation rates (EIR). However, in this model, the effects of malaria control interventions and clinical episodes on serological measurements were not assessed. This study monitors the use of antibody responses to P. falciparum crude extracts for assessing malaria transmission, compares seroconversion rates estimated from longitudinal data to those derived from cross-sectional surveys and investigates the effects of malaria control interventions on these measures in an area of declining malaria transmission. In addition, the validity of this model was evaluated by comparison with the alternative model.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29020949 PMCID: PMC5637097 DOI: 10.1186/s12936-017-2052-0
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Characteristics of survey participants
| 2000 | 2002 | 2008 | 2010 | 2012 | p value | |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 53.7 (234) | 48.4 (180) | 47.6 (256) | 47.2 (272) | 45.6 (250) | |
| Female | 46.3 (202) | 51.6 (192) | 52.4 (282) | 52.8 (304) | 54.4 (298) | 0.091 |
| Clinical malaria episodes/person | ||||||
| Min | 0 | 0 | 0 | 0 | 0 | |
| Mean | 1.6 | 1.1 | 1.09 | 0.20 | 0.03 | |
| Max | 14 | 17 | 13 | 2 | 1 | |
Characteristics of the longitudinal cohort
| Number of screened times during survey period | % of subjects (N = 359) | Age median |
|---|---|---|
| 2 | 30.6 (110) | 12.8 |
| 3 | 35.1 (126) | 12.3 |
| 4 | 18.4 (66) | 12.5 |
| 5 | 15.9 (57) | 36 |
Fig. 1Seroprevalence to P. falciparum malaria schizonts sch07/03 with age groups by survey
Fig. 2Fitting seroprevalence by reversible catalytic model against Pf Sh07/03 for each cross-sectional survey. Black dots represent the observed values, red lines indicate estimated seroconversion with the model and black broken lines indicate the 95% confidence interval (CI) with the likelihood ratio test. The sixth plot present the correlation between the seroconversion rate and the observed EIR given by entomologists
Seroconversion rates from catalytic models in cross-sectional surveys, their corresponding EIR [15] calculated from the serological measures and observed EIR given by entomologists
| Surveys period | SCR (95% CI) | Corresponding EIR | Observed EIR |
|---|---|---|---|
| 2000 | 0.22 (0.17–0.280) | 518.57 | 482.6 |
| 2002 | 0.126 (0.099–0.159) | 261.77 | 409.9 |
| 2008 | 0.094 (0.079–0.112) | 174.35 | 155.3 |
| 2010 | 0.073 (0.062–0.086) | 116.97 | 88.8 |
| 2012 | 0.042 (0.036–0.049) | 32.28 | 7.6 |
Fig. 3Trends of observed and estimated entomological inoculate rate (EIR), seroconversion rate (SCR) and seroreversion rate (SRR): a dynamic of observed entomological inoculate rate, EIR (black) calculated from parasitological measurements, seroconversion rate of anti-Pfsch07/03 and their corresponding entomological inoculate obtained by the catalytic model described previously [15], b comparison between observed and corresponding EIR obtained by the log–log calibration [15, 16], c evolution of SCR and SRR by years
Fig. 4Fitting seroprevalence by reversible catalytic model (a) and alternative catalytic model (b) for anti-Pf Sh07/03. For all these figures, the red curves were the seroprevalence obtained from models without covariates and their 95% likelihood ratio test confidence intervals and the green ones these from models according to the clinical attacks and the LLINs usage. The triangle points were the seroprevalences calculated among the observed antibodies response
Estimation of seroconversion and seroreversion rates from longitudinal and cross-sectional studies
| Study | Seroconversion (95% CI) | Seroreversion (95% CI) |
|---|---|---|
| Longitudinal survey | ||
| Without covariates | 0.284 (0.230–0.351) | 0.066 (0.051–0.085) |
| With covariates | 0.215 (0.171–0.269) | 0.041 (0.030 - 0.055) |
| Cross-sectional surveys | ||
| 2000 | 0.220 (0.173–0.280) | 0.006 (0.00–0.514) |
| 2002 | 0.126 (0.099–0.159) | 0.001 (0.00–0.02) |
| 2008 | 0.094 (0.079–0.112) | 0.017 (0.007–0.047) |
| 2010 | 0.073 (0.059–0.091) | 0.003 (0.00–0.024) |
| 2012 | 0.042 (0.036–0.049) | 0.057 (0.026–0.125) |
Estimation of parameters [respectively the relative risk (RR)] influencing seroconversion and seroreversion rates from longitudinal studies
| Covariates | SCR | SRR | ||||
|---|---|---|---|---|---|---|
| Effect | RR | p value | Effect | RR | p value | |
| Clinical episodes | 0.08 | 0.092 | < 0.001 | 0.24 | 0.786 | < 0.001 |
| Mosquito nets | − 2.57 | 0.076 | < 0.001 | 0.010 | 1.01 | < 0.001 |